We compared flow cytometric immunophenotyping results obtained by using the lysed whole blood method of sample preparation with those obtained by using Ficoll-Hypaque-separated cells on 44 consecutive specimens from patients with various hematologic malignancies. When the samples were analyzed as a group, seven antigens (CD2, CD3, CD5, CD11c, CD20, CD22, and CD34) demonstrated significantly different percentages of positively staining cells. When the samples were grouped by disease, results for patients with acute lymphocytic leukemia were discordant for CD22 and HLA-DR and results for patients with hairy cell leukemia were discordant for CD34. Most of the differences, however, were not with antigens critical to the evaluation of the malignancy. Additionally, the most frequent reason for differences in the percentage of positive cells was due to isotype control-based placement of the quadrant markers and not an actual discrepancy in staining. However, analysis of the CD34 antigen yielded eight instances in which staining of Ficoll-Hypaque-separated cells was essentially negative, but a clearly positive population was evident with the lysed preparation. This finding has important implications because of the prognostic significance of this antigen. Further studies are needed to determine the cause of this phenomenon.
The use of flow cytometry in the diagnosis of hematologic malignancies has been well documented as an adjunct diagnostic test for cytologic, pathologic, and histologic techniques (7) . Each discipline offers a unique contribution to the analysis of neoplastic cells, and the compilation of data from each specialty offers the clinician important and relevant information. The specific lineage assignment afforded by immunohistology and flow cytometry is valuable in therapy and prognosis (11) . As technology progresses in each of these fields, the compilation of data is more efficient and more reliable. Thus, improvements in technique become beneficial to the patient.
The advantages of flow cytometry-based methods for the analysis of leukemias and lymphomas are extensive. Flow cytometry-based methods are generally faster and less laborintensive than other comparable methods. Flow cytometry provides multiparameter, single-cell analysis, so that multiple markers on the same cell can be identified. In addition, it provides an investigator an objective means of determining a cell's phenotype, rather than depending on subjective viewer observations.
An important aspect of quality assurance in flow cytometry is sample preparation. In particular, density gradient-separated cells and lysed whole blood (LWB) methodologies are most frequently used. However, separated mononuclear cell preparations have been shown to exhibit selective loss of specific cell populations. This loss can be detrimental to analysis of specimens containing low numbers of neoplastic cells (9) . The use of a whole blood sample preparation methodology requires a significantly smaller sample volume. Immunophenotyping (with separated cell preparations) has been shown to be quite sensitive for the detection of minimal residual disease (6) , and the whole blood method is likely to prove to be equally suitable. Additionally, the whole blood method saves time and resources in the clinical laboratory. It is generally felt that the LWB method provides similar results when it is compared with the older methods (3). However, this has not been extensively studied in immunophenotypic analysis of hematologic malignancies.
In the study described in this paper, we evaluated the LWB method of sample preparation as a more rapid procedure for the flow cytometric analysis of hematologic samples by comparing the results with those obtained with Ficoll-Hypaque (FH)-separated cells. By using an LWB method instead of an FH-separated cell method for processing peripheral blood and bone marrow, a significant saving in laboratory turnaround time can be achieved while still producing reliable and relevant results.
MATERIALS AND METHODS

Specimens.
A total of 44 consecutive patient specimens were analyzed for a variety of leukocyte surface markers at the University of North Carolina Hospitals from May 1990 through September 1991. Samples from patients in the following diagnostic groups were analyzed: acute lymphoblastic leukemia (ALL), 2 peripheral blood (PB) samples and 11 bone marrow aspirate (BMA) samples; acute myelogenous leukemia (AML), 12 BMA samples; chronic lymphocytic leukemia (CLL), 9 PB samples and 5 BMA samples; and hairy cell leukemia (HCL), 5 PB samples. The diagnostic groups were further defined by subtype as follows. The two PB samples from patients with ALL were pre-B-cell ALL. Patients with ALL who provided BMA samples included five with pre-B-cell ALL, five with T-cell ALL, and one with pre-B-cell ALL with myeloid antigens. Patients in the AML group (all BMA) included two with M-0, four with M-2, three with M-3, one with M-4, one with myelodysplastic syndrome-refractory anemia with excess blasts, and one with unclassified AML arising from myelodysplastic syndrome. Among the PB samples from the CLL group, seven were from patients with classic B-cell CLL, one patient was diagnosed with Sezary syndrome, and one patient was classified as having T-gamma lymphoproliferative disorder. The BMA samples from the CLL group included three from patients with B-cell CLL, one from a patient with adult T-cell leukemia/lymphoma and one from a patient with B-cell CLL/lymphoma. Four of the patients in the HCL group were classified as having typical HCL and the remaining one was described as having HCL/prolymphocytic leukemia. PB specimens were collected directly into either EDTA-or heparin-anticoagulated tubes and were processed within 4 h of collection. BMAs were collected into heparinized syringes and were delivered directly to the Flow Cytometry Laboratory.
Mononuclear cell procedure. Heparinized PB specimens were centrifuged to obtain a buffy coat, with the plasma removed and discarded. The buffy coats were diluted 1:3 with RPMI-plus tissue culture medium (RPMI-1640 with penicillin, streptomycin, and glutamine; Tissue Culture Facility, Lineberger Cancer Research Center, University of North Carolina, Chapel Hill). Whole BMAs were diluted 1:3 in RPMI-plus. The diluted buffy coats or bone marrow was layered onto density gradients (Lymphocyte Separation Medium, Organon Teknika, Durham, N.C.), and the gradients were centrifuged to obtain the mononuclear cell fraction, which was aspirated and washed twice with RPMI-plus. The mononuclear cells were counted on a hemocytometer and were adjusted to a concentration of 10 7 cells per ml in RPMI-plus. The cells were divided into aliquots (100 l per tube) into staining tubes and were washed with buffer (phosphate-buffered saline [PBS], 0.1% bovine serum albumin, 0.1% sodium azide). Appropriate volumes of fluorochrome-conjugated monoclonal antibodies were added to each tube, and the cell suspensions were incubated for 30 min at 4ЊC. The preparations were washed twice with buffer and were resuspended in 1% paraformaldehyde for fixation prior to analysis.
Lysed procedure. Whole blood or BMAs were divided into aliquots (50 l) and were placed directly into staining tubes containing the appropriate volumes of fluorochrome-conjugated monoclonal antibodies. To ensure an optimum ratio of monoclonal antibody to cells, the specimen concentration was adjusted according to the total leukocyte count prior to processing. Any specimen with a leukocyte count greater than 10.0 ϫ 10 9 /liter was diluted with PBS to a final leukocyte count of between 5.0 ϫ 10 9 and 10.0 ϫ 10 9 /liter before staining. The preparations were mixed by gentle vortexing and were incubated at room temperature for 15 min. Two milliliters of a commercially available lysing solution (FACS Lysing Solution; Becton Dickinson Immunocytometry Systems [BDIS], San Jose, Calif.) was added to each tube, and the tubes were vortexed and incubated for 10 min at room temperature. Tubes were centrifuged for 5 min and were then washed with 2 ml of Dulbecco's PBS (Sigma, St. Louis, Mo.) with 0.1% sodium azide. The resulting cell suspensions were resuspended in 1% paraformaldehyde in PBS for fixation prior to analysis.
Monoclonal antibodies. Fluorescein isothiocyanate (FITC)-and phycoerythrin (PE)-conjugated monoclonal antibodies were used in various combinations, depending on the request of the ordering physician. Table 1 lists the antibodies used. All assay mixtures were stained as two-color combinations, FITC-and PE-labeled antibodies, in order to maximize the information obtained from each tube. Premixed antibody combinations were used when possible, limited by availability to the following combinations: CD45-CD14, CD3-HLA-DR, CD4-CD8, and immunoglobulin G1 (IgG1)-IgG2, (all obtained from BDIS) and IgG2-IgG1 (obtained from GenTrak, Inc., Plymouth Meeting, Pa.). Antibody concentrations (comparing antibody with the isotype control) were matched as closely as was practical without performing extensive titrations. In some cases it was necessary to pair isotype controls and specific monoclonal antibodies from different manufacturers. Our laboratory has performed comparison studies to show that these pairings yield acceptable results.
Flow cytometry. All assays were run on a FACScan flow cytometer (BDIS) equipped with an argon ion laser emitting at 488 nm. The flow cytometer was calibrated each day with Calibrite beads (BDIS) and AUTOCOMP (BDIS), as recommended by the manufacturer. List mode data were acquired in the CON-SORT 30 (BDIS) software program and were analyzed by the LYSYS (BDIS) software. Two-parameter dot plots were generated from each tube, and markers were set by using isotype controls (where appropriate) to calculate quadrant statistics.
List mode data analysis. List mode files were analyzed by using LYSYS (BDIS) software. Analysis gates were set using forward (FSC) and side (SSC) scatter. The cell population chosen for analysis depended on the nature of the case, i.e., low FSC and low SSC (lymphocytes) for mature lymphoid processes or slightly higher FSC and low SSC (blasts) for acute leukemia. The selection of the cell population was confirmed by the hematopathologist reviewing the case and was adjusted or reanalyzed as needed. All gates were verified by using CD45 and CD14 to identify and exclude unwanted events (debris, nonleukocytic cells, and monocytes) when appropriate. Fluorescence data (percentage of positive cells) for each monoclonal antibody pair were enumerated by setting quadrant markers on two-parameter dot plots by using the appropriate isotype controls. Markers were maintained at the isotype control settings for all succeeding plots unless there was sufficient evidence to warrant a change. In those cases, markers were set to separate the populations visually. Results were reported as the percentage of cells positive for each antigen, with dual-staining percentages reported as appropriate.
Statistical analysis. The differences in the percentage of positively staining cells were determined for each CD antigen. The significance of the differences was assessed by the paired t test. The correlation coefficient was also determined.
RESULTS
Staining of LWB and FH-separated cell suspensions. Fortythree samples of PB or BMAs from patients with various hematologic malignancies were stained with fluorochrome-labeled monoclonal antibodies (Table 1) . Each specimen was set up simultaneously by an LWB technique and after separation on FH gradients. Flow cytometric analysis was then carried out on these samples. The mean difference, correlation coefficient, and statistical significance of differences were determined for all antigens.
When they were examined as a group (samples from all 44 patients), 7 antigens demonstrated significantly different staining characteristics (P Ͻ 0.05) between LWB and FH-separated preparations (Table 6 ). Included in this group of antigens were CD2, CD3, CD5, CD11c, CD20, CD22, CD25, and CD34.
We also examined staining by disease category. In patients with ALL, two antigens (CD3 and CD20) had significantly different staining characteristics (Table 2) . Although it was not statistically different, the mean difference in CD34 staining was large (35.9%). Patients with AML demonstrated significantly different staining patterns for the CD2 and CD3 antigens (Table 3). The CD20, CD22, and HLA-DR antigens stained significantly different in patients with CLL (Table 4 ). In patients with HCL the CD34 antigen demonstrated significantly different staining patterns (Table 5) . Although not reaching significance, the mean difference for the CD11c antigen was large (44.5%).
Differences detected by visual histogram interpretation. Upon inspection of the plots we noted that the most frequent reason for differences in the percentages of positively staining cells was due to placement of the quadrant markers (Fig. 1) . In these cases, the populations of cells generally stained dimly. However, analysis of the CD34 antigen yielded seven instances in which staining of FH-separated cells was essentially negative, but a clearly positive population was evident with the LWB preparation ( Fig. 2A to G) .
DISCUSSION
We (14) and others (1, 4, 5, 12, 13) have demonstrated that different specimen processing methods (FH and LWB) can yield significantly different results in flow cytometric analyses. Differences were noted in the percentage of positively staining cells with normal controls (1, 5, 12, 13) and in specimens from human immunodeficiency virus-positive individuals (10, 14) . These data clearly demonstrate the need to document the effect of the chosen specimen preparation method on normal and abnormal patient specimens. In the present study we evaluated the effectiveness of the LWB specimen processing methodology on specimens from patients with various hematologic malignancies to determine if it is an acceptable technique for sample preparation.
In the analysis of our data, we determined the differences in the percentages of positively staining cells on FH-separated and LWB preparations. Markers were set on the basis of isotype control antibodies. Nineteen CD antigens were analyzed in four patient groups. As a group (44 patients), seven antigens demonstrated significantly different staining patterns. On a case-by-case basis, in 89 of 102 instances (82%) the percentages of positively staining cells were higher in the LWB preparations than in the FH-separated preparations. The T-cell marker CD3 yielded significantly different results in patients with ALL and AML. However, this marker is not critical to the evaluation of these diseases; therefore, the biological significance of this finding is limited. As with CD3, the difference in CD2 staining in patients with AML is of limited importance.
The two types of chronic leukemia included in our analysis, CLL and HCL, have unique surface antigenic characteristics which are used in their identification by flow cytometry. Cells from patients with CLL typically coexpress the CD5 and CD20 surface antigens, in addition to their monoclonal light chain restriction. Cells from patients with HCL characteristically coexpress CD22 and CD11c surface markers. In our analysis, the CD20 and CD22 antigens were significantly different in patients with CLL. However, while the analysis demonstrated a numerical difference, observation of the dot plots demonstrated that the cell clusters were similar in their fluorescence intensities and that the difference in the percentages of positive cells was due to different marker settings distinguishing positive and negative staining. Thus, the distribution of the isotype control has a significant effect on the percentage of dimly positively staining cells when data are reported as the percentages of positively staining cells. In these cases a descriptive report of staining results is appropriate.
The role of immunophenotyping in acute leukemia includes differentiation between ALL and AML, differentiation of subgroups of B-cell ALL from T-cell ALL, diagnosis of acute megakaryoblastic leukemia, and identification of leukemias expressing both myeloid and lymphoid antigens (3) . Some of the CD antigens useful for differentiating AML from ALL and Tfrom B-cell ALL include HLA-DR, CD34, CD10, CD19, and CD20 for B-cell ALL; CD2, CD5, CD7, CD34, and cytoplasmic CD3 for T-cell ALL; and CD13, CD33, and CD34 for AML. Both FH-separated and LWB preparations gave similar results in our patients with ALL and AML with the exception of CD20 in patients with ALL and CD2 and CD3 in patients with AML. However, the difference obtained with CD20 was also felt to be due to differences in marker settings, not a true difference in staining.
The CD34 antigen yielded significantly different results on the basis of the sample preparation method when all patients were grouped together but only in patients with HCL when the examination was done on a disease group basis. In eight patients the CD34 antigen was detected on leukemic cells in samples prepared by the LWB technique but not in cells prepared by FH separation. Significant differences were noted in three patients with acute leukemia (all BMA samples), one patient with chronic leukemia (PB sample), and four patients with HCL (all PB samples). This is an important finding because of the prognostic significance placed on the presence of the CD34 antigen in patients with acute leukemia (2, 11) . While the explanation for the difference is not known, several hypotheses could account for it. Use of the FH-separated preparation has been shown to lead to the loss of specific subsets of cells (5) . However, this explanation is not applicable since the leukemic cells in these samples were detected in tubes containing other antibodies. Another explanation could be that the CD34 antigen was modulated from the cell surface or blocked by components of FH during the separation. These explanations do not appear to be appropriate since CD34 was detected on FH-separated cells from other patients. One cannot rule out the possibility that the relatively weak staining of samples from patients with CLL and HCL by CD34 by the LWB technique is falsely positive. However, circulating progenitors have been documented in PB of patients with HCL (8) . Finally, the difference could be due to the monoclonal antibody used. Comparative studies with monoclonal antibodies from other manufacturers need to be conducted to determine if this is the case. Our data extend previous findings (1, 4, 5, 10, (12) (13) (14) 
